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Background: Although prevalence of co-existing type 2 inflammatory diseases (cT2) in 
asthma patients has been reported, limited data exist regarding their impact on asthma 
outcomes.
Objective: To assess the impact of cT2 burden on asthma outcomes and to evaluate patterns 
of clustering of cT2 in a real-world setting.
Methods: From medical records of 4.5 million enrollees in 650 primary care practices in the 
UK (January 2010–December 2017), patients with ≥1 diagnosis code for asthma at any time 
pre-index date (date of most recent asthma-related medical encounter) and ≥2 asthma-related 
prescriptions during the year before index date were categorized into the Global Initiative of 
Asthma (GINA) guideline severity steps. A cT2 burden score (range 0–9) was assigned 
based on the total number of co-existing conditions (allergic conjunctivitis, allergic rhinitis, 
anaphylaxis, eczema/atopic dermatitis, chronic rhinosinusitis, eosinophilic esophagitis, food 
allergy, nasal polyps, or urticaria) for which patients received a medical diagnosis. 
Multivariate regression models evaluated associations between cT2 burden score and asthma 
exacerbations and asthma control. Factor analysis was performed to assess which cT2 
comorbidities were correlated and exhibited patterns of clustering.
Results: Overall, 245,893 patients with asthma were included (mean [SD] age 44.8 [22.1] 
years; 43.8% male). Between 55% (GINA step 1) and 60% (GINA step 5) of asthma patients 
had a medical diagnosis for ≥1 other type2dx. Patients with increased cT2 burden were 
significantly more likely to experience asthma exacerbations and less likely to achieve 
asthma control.
Conclusion: Asthma patients with a higher cumulative cT2 burden score were more likely 
to experience worse asthma outcomes than those without any cT2 (burden score of 0).
Keywords: type 2 inflammation, asthma, exacerbations, control, comorbidities, burden
Introduction
Asthma is a heterogeneous respiratory disorder characterized by chronic airway 
inflammation with symptoms including wheezing, shortness of breath, chest tight-
ness, and coughing,1,2 all of which vary over time and in intensity. Affecting more 
than 300 million people worldwide, asthma has high epidemiologic, economic, and 
humanistic burden.2,3
Type 2 inflammation, driven by key cytokines including interleukins (IL)-4, -5 and 
-13—which are produced by T-helper 2 cells and type 2 innate lymphoid cells—is 
a unifying feature of classically defined allergic and other inflammatory diseases.4,5 
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Approximately 50–70% of asthma patients have type 2 
asthma, which is characterized by type 2 inflammation.6–8 
The Global Initiative for Asthma (GINA) guidelines 2019 
also highlight the type 2 phenotype among patients with 
severe asthma.9 Asthma is increasingly considered to be 
part of a multimorbidity syndrome,10–12 and a large propor-
tion of asthma patients report symptoms of co-existing type 2 
inflammatory diseases (cT2) such as eczema/atopic dermati-
tis, chronic rhinosinusitis with nasal polyposis, eosinophilic 
esophagitis, allergic rhinitis, or food allergies.13–17 Individual 
cT2 comorbidities can negatively impact patient quality of 
life and asthma-related outcomes.11,12,18,19
Although prevalence of cT2 among asthma patients 
based on patient self-report has been documented in the 
literature, limited data exist on characterizing cT2 burden 
in terms of medical service encounters or medical diag-
noses and its impact on asthma outcomes. This real-world 
study assessed the cT2 disease burden among patients with 
asthma and evaluated the association between cT2 burden 
and asthma outcomes, including exacerbations and overall 
asthma control. Additionally, this study assessed which 
cT2 comorbidities were correlated and exhibited patterns 
of clustering of medical service encounters.
Methods
Study Design
Anonymized data for the period between January 1, 2010, 
and December 31, 2017, were extracted from the Optimum 
Patient Care Research Database (OPCRD), a large UK pri-
mary care data source established and maintained by 
Optimum Patient Care (OPC), an independent research 
group. OPCRD contains electronic medical histories for 
>4.5 million enrollees who registered with a primary care 
provider for receiving outpatient medical services.20 
Because of the sufficient sample size and a preference for 
using recent data to better reflect current treatment patterns, 
data prior to 2010 were not extracted. To enable the com-
prehensive capture of longitudinal medical history on 
patients, the date of the last medical encounter for patients 
at the primary care site or the date of patient disenrollment 
from the site minus 6 months, whichever came first, was 
marked as the index date. Figure 1 is a pictographic repre-
sentation of the index date in relation to the observation 
window for asthma diagnosis and treatment patterns, medi-
cal diagnoses of conditions related to type2dx burden, and 
outcomes of interest.
Inclusion and Exclusion Criteria
Patients (adults and children ≥5 years) were included in 
the study if they had ≥1 diagnosis code for asthma at any 
time before the index date and had ≥2 prescriptions for any 
asthma medication per GINA guidelines in the year before 
the index date. All asthma patients were categorized as 
GINA 1 through 5 severity steps9 based on their asthma 
medication treatment patterns during the year before the 
index date. If patients stepped-up treatment during the 
1-year period, these patients were assigned the highest 
GINA step.
Patients were excluded if they had any chronic lower 
respiratory condition other than asthma recorded at any 
Figure 1 Retrospective database analysis study design.
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time, including chronic obstructive pulmonary disease, 
bronchiolitis obliterans, pulmonary fibrosis, pulmonary 
hypertension, and cystic fibrosis, since these are potential 
confounding factors. Bronchiectasis was not an exclusion 
criterion.
Co-Existing Type 2 Inflammatory Disease 
Burden
Type2dx burden was assessed at any time during the pre- 
index date period based on medical service encounters 
with Read codes for any one or more of the nine condi-
tions selected a priori based on expert consensus. These 
conditions included allergic conjunctivitis, allergic rhinitis, 
anaphylaxis, eczema (including atopic dermatitis), chronic 
rhinosinusitis, eosinophilic esophagitis, food allergy, nasal 
polyps, and urticaria. In the OPCRD, the conditions of 
interest were identified by the presence of Read codes, 
which are a coded thesaurus of clinical terms that provide 
standard vocabulary by which clinicians can record patient 
findings and procedures in health-data systems in the UK. 
Although some of the conditions listed above may not be 
cT2 in themselves (eg, anaphylaxis), we assumed that 
medical service encounters related to these conditions 
can serve as a measure of cT2 burden. Higher numbers 
of co-existing cT2 were assumed to reflect higher cT2 
burden; for example, patients with Read codes for both 
chronic rhinosinusitis and nasal polyps were considered to 
have greater cT2 burden than patients with only one of 
these medical diagnoses.
cT2 Comorbidity Burden Score and 
Patterns of Clustering of cT2
Descriptive statistics of baseline variables were assessed 
for all asthma patients meeting the study inclusion and 
exclusion criteria. Continuous variables were summarized 
using mean, standard deviation, and median. Binary and 
categorical variables were summarized using the number 
and percentage of non-missing observations by category.
Each patient was assigned a cT2 burden summary 
score (ranging from 0 to 9) based on the total number of 
conditions for which patients received medical services; 
higher scores indicated higher cT2 burden. The association 
between cT2 burden and asthma-related outcomes was 
evaluated using multivariable regression models. Finally, 
factor analysis—an item reduction technique aiming to 
find the smallest number of factors that can adequately 
explain the inter-relationships among the variables or 
items—was performed. This analysis assessed which med-
ical service encounters of the nine comorbidities were 
correlated with each other and exhibited patterns of 
clustering.
Outcomes of Interest
Asthma exacerbations and asthma control were measured 
for the 12 months before the index date. Severe asthma 
exacerbations were defined based on the American 
Thoracic Society (ATS) guidelines, which included the 
occurrence of one or more of the following: asthma- 
related hospital admission or accident and emergency 
(A&E) attendance, or an acute course of oral corticoster-
oids (OCS) for at least 3 days.21 Overall asthma control 
was defined as the absence of any of the following: an 
asthma-related A&E attendance, inpatient admission or 
outpatient department attendance, an acute course of 
OCS or an antibiotic prescription with a Read code for 
a lower respiratory consultation; and limited use of short- 
acting beta-2 agonists (average daily short-acting β-agonist 
dose not exceeding 200 μg salbutamol or >500 μg 
terbutaline).22–25
Associations between cT2 burden score (categorized as 
1, 2, 3, or 4+ vs 0 as the reference category) and the 
likelihood of having ≥2 asthma exacerbations and having 
asthma control was estimated by adjusting for age, gender, 
and GINA step as covariates in multivariable logistic 
regression models.
Software
All data-processing and analyses were performed with 
Stata SE version 14.2 or Stata MP/6 version 15.1.
Results
Baseline Characteristics
Based on the stepwise selection of patients meeting the 
inclusion and exclusion criteria, 245,893 asthma patients 
were included in the study (Figure 2). The mean (standard 
deviation [SD]) age of patients was 44.8 (22.1); 43.8% 
were male and 47.8% had controlled asthma; most patients 
(65.1%) had GINA treatment steps 3–5 (Table 1).
Among the asthma patients in the study cohort, 32.6% had 
medical service encounters for allergic rhinitis, 25.8% for 
eczema (including atopic dermatitis), 9.0% for chronic rhino-
sinusitis, 3.1% for nasal polyps, and <0.1% for eosinophilic 
esophagitis (Figure 3A includes a list of all nine 
comorbidities).
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The proportion of patients with a comorbidity burden 
score of ≥1 was similarly high (56–60%) among asthma 
patients across all GINA steps (Figure 3B). However, the 
proportion of patients with comorbidity burden score of ≥2 
and ≥3 increased from GINA step 1 (22%, 6%) to GINA 
step 5 (27%, 10%), respectively.
Overall, type2dx burden first peaked in individuals 10– 
19 years of age and thereafter declined with age. There 
was a particularly sharp decline in the burden between the 
age groups 20–29 and 30–39 years, among both males and 
females (Figure 3C and D).
Asthma Exacerbation Burden and Asthma 
Control
As expected, the asthma exacerbation burden increased 
with increasing GINA steps, ranging from 9% (step 1) to 
29% (step 5) of patients experiencing ≥1 asthma exacer-
bation and 2% (step 1) to 12% (step 5) of patients experi-
encing ≥2 asthma exacerbations during the 12 months 
before the index date (Figure 4A). Similarly, the 
proportion of patients with uncontrolled asthma increased 
from 53% (step 1) to 75% (step 5) (Figure 4B).
Association Between Type 2 
Inflammatory Disease Burden and 
Asthma Outcomes
Based on results of multivariable regression analysis (after 
controlling for covariates including patient age, gender, and 
Figure 2 Selection of eligible patients. aLung disease due to external agents, other 
than smoking, such as occupational agents; active chronic obstructive pulmonary 
disease; bronchiolitis obliterans; pulmonary fibrosis; pulmonary hypertension; cystic 
fibrosis. 
Abbreviations: OPCRD, Optimum Patient Care Research Database; QOF, Quality 
and Outcomes Framework.
Table 1 Baseline Characteristics
Variable Diagnosed Asthma  
(N = 245,893)
Age (years), mean (SD), median 44.8 (22.1), 45.0
Male, n (%) 107,763 (43.8)
Smoking status, n (%)
Never smoked 140,829 (60.5)
Current smoker 37,218 (16.0)
Ex-smoker 54,912 (23.6)
No data on smoking status 12,934 (5.3)
FEV1% predicted, mean (SD)
a, median 85.3 (22.4), 87.0











Patients having overall asthma controld, 
n (%)
117,423 (47.8)
Notes: aNumber of patients with non-missing data = 110,946. bGINA step 1: short- 
acting relievers only; GINA step 2: low-dose inhaled corticosteroid (ICS) without 
controllers, leukotriene receptor (LTRA) without controllers, theophylline without 
controllers, sodium cromoglicate, or nedocromil sodium; GINA step 3: medium- or 
high-dose ICS without controllers, low-dose ICS/long-acting beta agonist (LABA), low- 
dose ICS/long-acting muscarinic antagonist (LAMA), low-dose ICS without LABA or 
LAMA plus LTRA and/or theophylline, LABA and/or LAMA without ICS, LTRA plus 
theophylline without ICS; GINA step 4: medium- or high-dose ICS/LABA, medium- or 
high-dose ICS/LAMA, medium- or high-dose ICS plus LTRA and/or theophylline, low- 
dose ICS/LABA plus ≥1 controller, low-dose ICS/LAMA plus ≥1 controller, ≥3 con-
trollers without ICS; GINA step 5: maintenance OCS plus other treatment or anti- 
immunoglobulin-E therapy. cIncludes one or more occurrences of any of the following: 
asthma-related hospital admission or A&E attendance or an acute course of oral 
corticosteroids. dControlled asthma, defined as the absence of the following: an 
asthma-related A&E attendance, inpatient admission or outpatient department atten-
dance, an acute course of oral corticosteroids with evidence of a lower respiratory 
consultation, an antibiotic prescribed with evidence of a lower respiratory consulta-
tion; and limited use of short-acting beta-2 agonists (average daily short-acting β-agonist 
dose not exceeding 200 μg salbutamol or >500 μg terbutaline). 
Abbreviations: ATS, American Thoracic Society; FEV1, forced expiratory flow in 
1 second; GINA, Global Initiative for Asthma; SD, standard deviation.
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GINA step), patients with a higher cT2 burden score were 
significantly more likely to experience ≥2 asthma exacerba-
tions (2 comorbidities: odds ratio [OR] 1.16 [1.10–1.23]; 3 
comorbidities: OR 1.35 [1.24–1.47]; ≥4 comorbidities: OR 
1.74 [1.52–1.95]; Figure 5A) and significantly less likely to 
achieve asthma control (2 comorbidities: OR 0.86 [0.83– 
0.88]; 3 comorbidities: OR 0.77 [0.74–0.88]; ≥4 comorbid-
ities: OR 0.67 [0.63–0.72]; Figure 5B) compared with patients 
without any type 2 inflammatory diseases (ie, cT2 burden 
score of 0, reference group).
Clustering of Medical Encounters for the 
Nine a Priori Conditions Related to 
Type2dx Burden
Bivariate analysis was conducted to estimate the OR for the 
occurrence of medical diagnosis for each of the nine conditions 
with every other condition. Asthma patients with a diagnosis of 
nasal polyps were also more likely to have a diagnosis of 
allergic rhinitis and chronic rhinosinusitis. Asthma patients 
with codes for food allergies were also more likely to have 
codes for anaphylaxis and eczema (see Figure S1A). 
Additionally, asthma patients with codes for urticaria were 
also more likely to have codes for eczema, food allergy, ana-
phylaxis, and allergic rhinitis (Figure S1A–H).
When all nine conditions were evaluated in a single- 
factor analysis to assess clustering of any medical service 
encounters related to cT2, it was revealed that patients 
with asthma tended to have type2dx disease burden in 
three distinct clusters: the first cluster, comprising food 
allergy and anaphylaxis; the second cluster, comprising 
chronic rhinosinusitis and nasal polyps; and the third clus-
ter, which included allergic rhinitis, eczema, allergic con-
junctivitis, and urticaria (Figure 6).
Discussion
Type 2 asthma is a widely prevalent type of persistent, 
uncontrolled asthma26 and includes allergic asthma and 
A B
C D
Figure 3 (A) Proportion of asthma patients with medical encounters related to type 2 comorbidities. (B) Comorbidity burden score by GINA steps among asthma patients. 
(C) Comorbidity burden score by age category in females. (D) Comorbidity burden score by age category in males. 
Abbreviation: GINA, Global Initiative for Asthma.
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eosinophilic asthma phenotypes, which have overlapping 
pathophysiological mechanisms.8 It is well established that 
IL-4 and IL-13 are key drivers of cT2 such as atopic 
dermatitis, allergic rhinitis, nasal polyps, and eosinophilic 
esophagitis.27,28 Although prevalence of cT2 among 
patients with asthma has been reported based on patient 
self-reports, this study provides insights into the cT2 bur-
den in terms of medical diagnosis of conditions and ser-
vice encounters related to cT2 among patients with 
asthma.
While the impact of cT2 such as allergic rhinitis on 
healthcare resource utilization among asthma patients has 
been previously investigated,29–31 few studies, to our 
knowledge, have investigated the impact of overall cT2 
burden on asthma exacerbations and asthma control. One 
cross-sectional, observational study found that co-existing 
allergic rhinitis was associated with an incremental 
adverse impact on the level of asthma control;32 mean-
while, a second cross-sectional, observational study found 
that patients reporting severe rhinitis had worse asthma 
control than those with mild or no rhinitis symptoms.33 
The trends observed in these two cross-sectional studies 
are reflected in our study,32 as asthma patients with an 
increased number of cT2 had decreased asthma control 
compared with asthma patients with fewer cT2. 
However, we believe that our study is the first to reveal 
the impact of multiple cT2 on asthma control, beyond 
allergic rhinitis.
Results of this study also confirm that asthma patients 
with cT2 had a higher risk of experiencing severe exacer-
bations compared with asthma patients with fewer cT2, 
which is supported by previously published evidence 
A
B
Figure 4 Outcomes of interest categorized by GINA step. (A) Proportion of patients with asthma exacerbation. (B) Proportion of patients having overall asthma control. 
Abbreviation: GINA, Global Initiative for Asthma.
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demonstrating the association between asthma and comor-
bid allergic rhinitis and increased exacerbations.34,35 
Among asthma patients, the burden of cT2 first peaked 
between the age 5–9 and age 10–19 cohorts, then appeared 
to decline across the older age groups. This trend is not 
unusual as it is understood that some children can outgrow 
cT2 such as eczema36 and food allergies.37 Burden of type 
2 comorbidities was high across all GINA steps, with the 
majority of asthma patients having a diagnosis for at least 
one other cT2.
Previous studies have demonstrated that allergic rhi-
nitis is a prevalent comorbidity among patients with 
A B
Figure 5 (A) Odds ratios for relationship between type 2 disease-related comorbidity burden score and asthma exacerbations. (B) Odds ratios for type 2 disease-related 
comorbidity burden score and achievement of asthma control. Logistic regression analysis was conducted using the following covariates: patient age, gender, and Global 
Initiative for Asthma (GINA) step.
Figure 6 Clustering of medical service encounters related to type 2 inflammatory diseases among patients with asthma. Size of circles is proportional to the prevalence of 
the comorbidity. The width of the lines connecting the two comorbidities is proportional to the strength of their association. The color of the lines indicates the direction of 
association: positive (teal) or negative (red). The position of the comorbidities is based on the rotated eigenvalues from the Principal Component Analyses, and shows the 
nearness based on co-occurrence frequencies and association strengths and directions.
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asthma,38–43 and even more so among patients with 
uncontrolled moderate-to-severe asthma, with <74% of 
these patients also presenting with allergic rhinitis.44 In 
this study, associations between comorbidities, based on 
the likelihood ratios of occurrence, were very strong for 
anaphylaxis and food allergy, and strong between 
chronic rhinosinusitis and nasal polyps. The strong asso-
ciation between anaphylaxis and food allergy observed 
in this study is not surprising, as food allergy is 
a common cause of anaphylaxis.45 Additionally, similar 
to our findings in primary care, the strong association 
between medical diagnosis of chronic rhinosinusitis and 
nasal polyps is well documented for other settings, since 
nasal polyps is a phenotype of chronic rhinosinusitis 
(clinical trials, health surveys, and multicenter observa-
tional studies).13–15,46
A key strength of the current study is the use of real- 
world, population-based data and the large sample size.47 
However, our study findings must also be interpreted in 
light of some limitations. As is the case with real-world 
studies, which use healthcare service encounter data-
bases, this analysis will under-represent loss of asthma 
control during situations in which the patient already had 
a prescription of an OCS or SABA on-hand, which was 
subsequently used during an episode of worsening in 
asthma symptoms. Because this study used service 
encounter data, to the extent that physicians use READ 
codes for eczema/AD and urticaria/atopy interchange-
ably, it is not possible to differentiate between these 
conditions. It was not possible to determine how the 
clustering of type comorbidities differed according to 
early- and late-onset asthma. The OPCRD did not include 
information on the severity of the cT2; hence, the novel 
comorbidity burden score developed in this study only 
captured disease burden in terms of the number of cT2 
rather than both the number and severity of conditions 
related to type 2 inflammation. Additionally, it is possible 
that there was an under-representation of the disease 
burden due to the lack of a standardized usage of Read 
codes for specific cT2 and asthma, or because patients 
may have been self-managing some of the conditions, 
especially mild rhinitis and eczema, with over-the- 
counter medications. The resulting data from the prespe-
cified analyses in this study suggest that the diagnosis of 
urticaria as used by clinicians increases the risk of asthma 
exacerbations and, to some extent, validates it. 
Additionally, results from a previous study suggest that 
at least chronic spontaneous urticaria is associated with 
increased T2 markers.48 Although urticaria may be 
accompanied by angioedema or angioedema may occur 
independently, angioedema was not included in the 
a priori analysis plan. Therefore, it is possible that inclu-
sion of both components separately may provide addi-
tional information related to cT2. Another limitation is 
that food allergy may be overestimated in the current 
study; however, it is associated with increased asthma 
exacerbation risk.
Conclusions
This real-world, retrospective database study has demon-
strated that patients with asthma, irrespective of GINA 
step, received medical service encounters related to cT2, 
thereby increasing resource use among asthma patients. 
The presence of type 2 comorbidities is associated with 
a higher risk of exacerbations and lower asthma control. 
Given that the presence of cT2 complicates the manage-
ment of asthma and is associated with higher risk of 
exacerbations and lower asthma control, clinicians may 
consider the assessment of type 2 comorbidity burden in 
their evaluation of patients with moderate-to-severe 
asthma.
Abbreviations
A&E, accident and emergency; ATS, American Thoracic 
Society; cT2, co-existing type 2 inflammatory diseases; 
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